Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
In a significant legal win for GSK plc (NYSE:GSK), on Friday, a Florida State Court ruled in favor of the pharmaceutical giant, excluding the plaintiff's expert testimonies that claimed ranitidine, a drug once sold under the Zantac brand, was a significant risk factor for prostate cancer.
周五，佛罗里达州一家州法院对药品巨头葛兰素史克（NYSE: GSK）做出了重大胜利的裁决，剔除了原告的专家证言。原告声称，曾经销售的医药品牌赞替丁是攀升前列腺癌风险的一个重要因素。
The court deemed the expert testimony unreliable, reinforcing the broader scientific consensus that ranitidine does not pose a consistent or reliable cancer risk.
法院认定专家证言不可靠，进一步强化了更广泛的科学共识：赞替丁并不会带来一致或可靠的癌症风险。
This decision aligns with a December 2022 ruling by Judge Rosenberg in the federal multidistrict litigation (MDL), which also dismissed expert evidence brought by plaintiffs alleging a link between ranitidine and several cancers, including bladder, esophageal, gastric, liver, and pancreatic cancers.
此次裁决与2022年12月罗森伯格（Rosenberg）法官在联邦多区域诉讼（MDL）中做出的裁决一致。该裁决也驳回了原告提出的专家证据，声称赞替丁和多种癌症（包括膀胱癌、食道癌、胃癌、肝癌和胰腺癌）之间存在联系。
Also Read: Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer.
另外阅读消息：行业板块支持葛兰素史克努力停止与胃酸反流药赞替丁有关的70,000起引发癌症的诉讼。
Both the Florida and MDL courts concluded that the methodologies used by plaintiffs' experts did not meet the Daubert standard, a key legal benchmark for scientific evidence.
佛罗里达州和联邦MDL法院均得出结论，原告专家所使用的方法未达到道伯特标准，这是科学证据的关键法律基准。
The scientific consensus, based on 16 epidemiological studies examining ranitidine use, has consistently shown no reliable evidence linking the drug to cancer risk.
基于16项以赞替丁用药为研究对象的流行病学研究，在科学共识的基础上，一致表明赞替丁与癌症风险没有可靠的证据关联。
The Florida State Court's ruling reflects this stance and safeguards against what GSK argues is "litigation-driven" science from entering legal proceedings.
佛罗里达州法院的裁决反映了这一立场，并防范了葛兰素史克所认为的“以诉讼为驱动”的科学进入法律程序。
GSK welcomed the ruling, stating it would now seek the dismissal of the upcoming Wilson case in Florida, where similar allegations about ranitidine and prostate cancer had been made.
葛兰素史克对此裁决表示欢迎，并表示将寻求不予受理即将在佛罗里达州开庭的威尔逊案。威尔逊案相似，是有关赞替丁和前列腺癌的指控。
Earlier this month, Jury in the Joiner case in Illinois state court found GSK not liable for the plaintiff's colorectal cancer.
本月早些时候，伊利诺伊州法院的乔伊纳案陪审团判定，葛兰素史克不承担原告的结肠癌责任。
In July, GSK reached a confidential settlement with Ronald Kimbrow, resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement.
今年7月，葛兰素史克与罗纳德·金布罗（Ronald Kimbrow）达成机密和解，解决了他在伊利诺伊州法院提起的案件。在此和解中，葛兰素史克不承认任何责任。
The case was dismissed.
此案已被解散。
According to a May report, Pfizer Inc. (NYSE:PFE) settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.
根据5月的一份报告，辉瑞公司（NYSE:PFE）已和解了1万起指控其隐瞒赞替丁胃酸反流药有癌症风险的诉讼，这标志着该诉讼的最大解决方案。
In April, Sanofi SA (NASDAQ:SNY) announced an agreement in principle to settle approximately 4,000 lawsuits in the U.S. linked to the discontinued heartburn drug Zantac.
今年4月，法国赛诺菲安万特公司（Sanofi SA，纳斯达克代码：SNY）宣布原则上同意解决并购有关停售的胃酸反流药赞替丁的约4,000起诉讼。
Price Action: GSK stock is down 0.56% at $41.17 during the premarket session at last check Friday.
周五盘前，葛兰素史克股价为41.17美元，下跌0.56%。
- Oral Vaccine-Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside.
- 口服疫苗针对的便宜股票Vaxart处境独特，分析师预计涨幅近83%。
Photo by ParentingPatch via Wikimedia Commons
图片由ParentingPatch通过维基媒体公共领域共享许可证发布。